[Screening for prostate cancer: an up date].
Recently, large prospective randomized controlled trials such as the European Randomized Study of Screening for Prostate Cancer(ERSPC), the subsequent Goteborg study, and the alternative analysis of the Prostate, Lung, Colorectal, and Ovarian (PLCO)Cancer Screening Trial conducted in the USA, demonstrated very important evidence contributing to screening for prostate cancer. In the Goteborg study, the median mortality reduction in the screening group during 14 years of follow-up was 44%, according to an intention-to-screen analysis. Introducing PSA-based screening could lead to evident mortality reduction and the prevention of metastatic disease progression, which may decrease QOL. Furthermore, establishing an optimal screening system that includes more accurate detection methods, minimally invasive treatment and active surveillance strategy(which minimizes over detection, overtreatment, and loss of QOL due to treatment), would improve the clinical validity of PSA screening. It is very important to conduct PSA-based screening according to well-balanced guidelines published by the Japanese Urological Association.